Ku­ra’s $150M PIPE; Lil­ly’s in­vest­ment in Prism Bi­o­Lab; An­no­vis de­lays PhI­II da­ta, cit­ing ‘da­ta clean­ing’

Plus, news about IMU Bio­sciences, ZWI Ther­a­peu­tics and Sagimet Bio­sciences:

Ku­ra On­col­o­gy’s $150M PIPE: The biotech is rais­ing funds from a stock sale to its ex­ist­ing in­vestors, in­clud­ing EcoR1 Cap­i­tal, an af­fil­i­ate of Deer­field Man­age­ment and Su­vret­ta Cap­i­tal Man­age­ment. It’s sell­ing at $17.25 a share, a 29% pre­mi­um to Ku­ra’s clos­ing price on Tues­day. The news sent the San Diego biotech’s stock $KU­RA up near­ly 50% Wednes­day morn­ing. The $150 mil­lion will like­ly ex­tend Ku­ra’s run­way out to 2027. The com­pa­ny ex­pects to share da­ta next week from a com­bi­na­tion study of its lead can­di­date, ziftomenib, in acute myeloid leukemia. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER